Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55(6):749–753

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ng SC, Shi HY, Hamidi N et al (2017) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390(10114):2769–2778

Article  PubMed  Google Scholar 

Tang LY, Rawsthorne P, Bernstein CN (2006) Are perineal and luminal fistulas associated in Crohn’s disease? A population-based study. Clin Gastroenterol Hepatol 4(9):1130–1134

Article  PubMed  Google Scholar 

Hart AL, Lomer M, Verjee A et al (2017) What are the top 10 research questions in the treatment of inflammatory bowel disease? A priority setting partnership with the James Lind Alliance. J Crohns Colitis 11(2):204–211

Article  PubMed  Google Scholar 

Tozer PJ, Burling D, Gupta A, Phillips RK, Hart AL (2011) Review article: medical, surgical and radiological management of perianal Crohn’s fistulas. Aliment Pharmacol Ther 33(1):5–22

Article  CAS  PubMed  Google Scholar 

Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340(18):1398–1405

Article  CAS  PubMed  Google Scholar 

Regueiro M, Mardini H (2003) Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 9(2):98–103

Article  PubMed  Google Scholar 

Maser EA, Villela R, Silverberg MS, Greenberg GR (2006) Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol 10:1248–1254

Article  Google Scholar 

Chaparro M, Barreiro-de Acosta M, Echarri A et al (2019) Correlation between anti-TNF serum levels and endoscopic inflammation in inflammatory bowel disease patients. Dig Dis Sci 64(3):846–854

Article  CAS  PubMed  Google Scholar 

Billiet T, Cleynen I, Ballet V et al (2016) Prognostic factors for long-term infliximab treatment in Crohn’s disease patients: a 20-year single centre experience. Aliment Pharmacol Ther 44(7):673–683

Article  CAS  PubMed  Google Scholar 

Davidov Y, Ungar B, Bar-Yoseph H et al (2017) Association of induction infliximab levels with clinical response in perianal Crohn’s disease. J Crohns Colitis 11(5):549–555

PubMed  Google Scholar 

Yarur AJ, Kanagala V, Stein DJ et al (2017) Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther 45(7):933–940

Article  CAS  PubMed  Google Scholar 

Strik AS, Löwenberg M, Buskens CJ et al (2019) Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn’s disease patients. Scand J Gastroenterol 54(4):453–458

Article  CAS  PubMed  Google Scholar 

El-Matary W, Walters TD, Huynh HQ et al (2019) Higher postinduction infliximab serum trough levels are associated with healing of fistulizing perianal Crohn’s disease in children. Inflamm Bowel Dis 25(1):150–155

Article  PubMed  Google Scholar 

Ruemmele FM, Rosh J, Faubion WA et al (2018) Efficacy of adalimumab for treatment of perianal fistula in children with moderately to severely active Crohn’s disease: results from IMAgINE 1 and IMAgINE 2. J Crohns Colitis 12(10):1249–1254

Article  PubMed  PubMed Central  Google Scholar 

Plevris N, Lyons M, Jenkinson PW et al (2019) Higher adalimumab drug levels during maintenance therapy for Crohn’s disease are associated with biologic remission. Inflamm Bowel Dis 25(6):1036–1043

Article  PubMed  Google Scholar 

Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT (2018) Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn’s disease. Inflamm Bowel Dis 24(10):2266–2271

Article  PubMed  PubMed Central  Google Scholar 

De Gregorio M, Lee T, Krishnaprasad K, Amos G, An YK, Bastian-Jordan M (2022) Higher anti-tumor necrosis factor-α levels correlate with improved radiologic outcomes in Crohn’s perianal fistulas. Clin Gastroenterol Hepatol 20(6):1306–1314

Article  PubMed  Google Scholar 

Freeman K, Connock M, Auguste P et al (2016) Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn’s disease: systematic reviews and economic modelling. Health Technol Assess 20(83):1–288

Article  PubMed  PubMed Central  Google Scholar 

Llinares-Tello F, de Salazar JR, Gallego JM et al (2012) Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab. Clin Chem Lab Med 50(10):1845–1847

Article  CAS  PubMed  Google Scholar 

Ruiz-Argüello B, del Agua AR, Torres N, Monasterio A, Martínez A, Nagore D (2013) Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 51(12):e287–e289

Article  PubMed  Google Scholar 

Tielbeek JA, Bipat S, Boellaard TN, Nio CY, Stoker J (2014) Training readers to improve their accuracy in grading Crohn’s disease activity on MRI. Eur Radiol 24(5):1059–1067

Article  PubMed  Google Scholar 

Braithwaite GC, Lee MJ, Hind D, Brown SR (2017) Prognostic factors affecting outcomes in fistulating perianal Crohn’s disease: a systematic review. Tech Coloproctol 21(7):501–519

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papamichael K, Vande Casteele N, Jeyarajah J, Jairath V, Osterman MT, Cheifetz AS (2021) Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn’s disease: an ACCENT-II post hoc analysis. Am J Gastroenterol 116(5):1007–1014

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gu B, Venkatesh K, Williams AJ et al (2022) Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease. World J Gastroenterol 28(23):2597–2608

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geldof J, Iqbal N, LeBlanc JF et al (2022) Classifying perianal fistulising Crohn’s disease: an expert consensus to guide decision-making in daily practice and clinical trials. Lancet Gastroenterol Hepatol 7(6):576–584

Article  PubMed  Google Scholar